VVA
KNTE

Vida Ventures Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Vida Ventures Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,207,772
Closed -$5.23M – 7
2023
Q4 		$5.23M Hold
2,207,772
– – 6.23% 5
2023
Q3 		$3.09M Hold
2,207,772
– – 4.78% 6
2023
Q2 		$6.69M Hold
2,207,772
– – 8.73% 4
2023
Q1 		$13.8M Hold
2,207,772
– – 18.88% 3
2022
Q4 		$13.5M Hold
2,207,772
– – 18.1% 2
2022
Q3 		$26.4M Sell
2,207,772
-539,661
-20% -$7.06M 23.68% 2
2022
Q2 		$34.6M Hold
2,747,433
– – 29.28% 1
2022
Q1 		$30.9M Hold
2,747,433
– – 17.99% 2
2021
Q4 		$48.7M Hold
2,747,433
– – 18.21% 2
2021
Q3 		$63.2M Hold
2,747,433
– – 18.11% 2
2021
Q2 		$64M Hold
2,747,433
– – 16.04% 3
2021
Q1 		$85.6M Buy
2,747,433
+359
+0% +$12.5K 21.63% 2
2020
Q4 		$109M Buy
+2,747,074
New +$110M 22.43% 2

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vida Ventures Advisors's KNTE Position: Q1 2024 in Review

Vida Ventures Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 2,207,772 shares — an estimated $5.23M sold.

Vida Ventures Advisors first reported a position in KNTE in Q4 2020 and held it in 13 quarters. The position peaked at $109M in Q4 2020. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • Vida Ventures Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Vida Ventures Advisors sold 2,207,772 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $5.23M.
  • Vida Ventures Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • Vida Ventures Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $109M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Vida Ventures Advisors's 13F filing for Q1 2024, filed 12 Apr 2024.